Full-Time
Key Account Manager
Mobile Surgery
Philips
Healthcare technology for diagnosis, care, wellness
Compensation Overview
$195k - $225k/yr
No H1B Sponsorship
Knoxville, TN, USA + 1 more
More locations: Nashville, TN, USA
In Person
Must reside in or within commuting distance to Nashville or Knoxville; overnight travel up to 75% is required.
Bachelor's
 Sales & Account Management (1) |
|---|
- At least 5 years of medical device sales experience selling directly into operating rooms.
- Ability to sell capital equipment into operating rooms; capital equipment experience is highly preferred.
- Radiology sales experience is preferred.
- Demonstrated solution-selling and execution skills in a complex team-selling environment.
- A Bachelor of Science or Bachelor of Arts degree in a related discipline, or equivalent experience.
- Ability to perform the minimum physical, cognitive, and environmental requirements for the sales position with or without accommodation.
- Must reside in or within commuting distance to Nashville or Knoxville, Tennessee.
- Ability to travel overnight up to 75%.
- United States work authorization is required, and candidates requiring sponsorship for a work-authorized visa are not eligible.
- Serve as the primary point of contact for Mobile Surgery decision-makers inside and outside hospitals.
- Identify, develop, and close Mobile Surgery opportunities involving C-Arms and services in installed, competitive, and new-construction laboratories and operating rooms.
- Collaborate with Cardiovascular Fixed System Account Managers, Interventional Guided Therapy Devices, Cardiovascular Ultrasound, Enterprise Diagnostic Informatics in Cardiology, Out of Hospital Business Development, Precision Diagnosis, Connected Care Patient Monitoring, Account Executives, Specialists, Services, and Solutions teams.
- Establish territory growth plans and strategic initiatives and translate them into clear objectives and targets.
- Develop and continually refine business strategies for key accounts, customers, and the territory based on the competitive landscape, business models, product features, service offerings, and positioning.
- Document the territory install base for represented solutions and establish plans to address assigned accounts, including breakthrough competitive accounts and segment strategy.
- Assess the market potential of the territory.
- Drive the sales process by uncovering compelling customer events, engaging stakeholders, developing coaches, executing C-Arm demonstrations, and escalating as appropriate.
- Establish and maintain effective relationships with external and internal customers by delivering customer-centric solutions based on customer needs and pain points.
- Capital equipment sales experience.
- Experience selling into Radiology.
Philips develops health technology across professional medical devices, connected care, and consumer health products. Its offerings include diagnostic imaging and image-guided therapy, patient monitoring and clinical informatics, and everyday wellness products like oral and personal care. The company increasingly delivers integrated solutions through a Healthcare-as-a-Service subscription model and long-term partnerships with hospitals and health systems. Its aim is to improve people’s health and well-being by making advanced health technology easier to access and integrate into care.
Company Size
N/A
Company Stage
IPO
Headquarters
Andover, Minnesota
Founded
1891
Simplify's Take
What believers are saying
- Q2 2026 sales rose 4%, and Philips raised 2026 margin guidance.
- June 2026 IntelliVue 6000 targets rural hospitals and ASCs with lower-cost enterprise monitoring.
- August 2026 monitoring partnerships with Blue Spark, Caretaker, and Cuviva expand hospital-at-home reach.
What critics are saying
- FDA consent decree still restricts Philips Respironics U.S. sleep-device manufacturing in 2026.
- August 2026 Brilliance CT recall shows unresolved quality control failures across imaging hardware.
- July 2026 China pressure and delayed U.S. orders hit bookings; margin depends on refunds.
What makes Philips unique
- Philips spans imaging, monitoring, and consumer health, reducing dependence on any single procedure area.
- Its open monitoring ecosystem links hospital and home devices through partner integrations and software.
- Philips sells enterprise-grade workflows, not standalone hardware, through diagnostics and connected-care platforms.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Health Savings Account/Flexible Spending Account
Company News
The global remote patient monitoring market is expected to grow from $67.3 billion in 2026 to $117.9 billion by 2033, registering a CAGR of 8.3%. Growth is driven by rising chronic disease prevalence, expanding telehealth services and increasing demand for home-based healthcare solutions. Devices and hardware account for nearly 38% of market share, led by connected blood pressure monitors, glucometers and wearable health trackers. North America holds approximately 41% of the global market, supported by strong digital healthcare infrastructure and favourable reimbursement policies. Asia Pacific is emerging as the fastest-growing region, driven by healthcare digitisation, telemedicine expansion and rising smartphone penetration. Leading players include Philips Healthcare, Medtronic, GE HealthCare and Abbott Laboratories, focusing on AI integration and cloud connectivity to enhance remote care delivery.
<img src="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp" alt="Philips Respironics Reaches Final Agreement with US Regulators on Sleep Apnea Device Recall. " class="wp-image-78777" srcset="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp 700w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-300x161.webp 300w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-290x155.webp 290w" sizes="(max-width: 700px) 100vw, 700px">What You Should Know: – Philips Respironics, a subsidiary of Royal Philips, has finalized a consent decree with the US Department of Justice (DOJ) and Food and Drug Administration (FDA) to address issues raised during a 2021 inspection of a Philips facility in Pennsylvania.– The agreement focuses on Philips Respironics’ operations in the US, particularly regarding the recall of certain sleep and respiratory care devices.– The company’s focus will now be on completing remediation efforts, ensuring patient safety, and regaining regulatory approval to resume sales of new devices in the US.Focus on Remediation and ComplianceThe consent decree outlines a roadmap for Philips Respironics to:Prioritize Recall Remediation: Philips will continue efforts to remediate millions of sleep apnea and respiratory care devices recalled in June 2021 due to potential health risks associated with degraded sound abatement foam.Independent Oversight: Independent experts will be brought in to review recall remediation efforts and ensure Philips Respironics’ business operations comply with FDA regulations.Continued Patient Support: Philips Respironics can continue servicing existing devices in the hands of patients and healthcare providers. Additionally, they can sell accessories, consumables, and replacement parts for these devices.Sales Restrictions Remain in USThe FDA has not yet authorized Philips Respironics to resume sales of new CPAP, BiPAP, or other respiratory care devices in the US. This restriction will remain in place until Philips meets the requirements outlined in the consent decree.Global Sales Continue with RestrictionsPhilips Respironics can continue to sell new devices, accessories, consumables, and replacement parts outside the US, subject to specific requirements.Safety of Devices with New Foam ConfirmedPhilips Respironics has conducted tests on devices using a new silicone sound abatement foam and found no safety issues. Patients can continue to use these devices following the instructions for use.Financial ImpactPhilips anticipates incurring costs associated with remediation activities and profit disgorgement related to US sales. These costs are estimated at 100 basis points in 2024. The company’s previously announced 2023-2025 financial outlook remains unchanged, already factoring in the consent decree. “Strengthening patient safety and quality remains Philips’ highest priority and the increased scrutiny will help us to improve even more
Following a recall of millions of its breathing machines that began in mid-2021, Phillips Respironics announced Monday that it would halt sales of all such machines within the United States.
In June of 2021, Philips began a recall of over five million of its breathing devices due to toxic fume and substances emanating from the devices’ sound abatement foam.
February 2019 – Koninklijke Philips launched the EPIQ Elite ultrasound system in the market.